Second primary malignancies after CAR T-cell therapy: A systematic review and meta-analysis of 5,517 lymphoma and myeloma patients.

Tobias Tix Mohammad Alhomoud Roni Shouval Edward Robert Scheffer Cliff Miguel-Ángel Perales David M Cordas Dos Santos Marion Subklewe

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

These data raise awareness of SPM as a clinically relevant long-term adverse event in patients receiving CAR T-cell therapy. However, our findings do not indicate that SPM frequency is higher with CAR-T versus previous standard-of-care strategies.

Keyphrases

cell therapy
stem cells
mesenchymal stem cells
newly diagnosed
end stage renal disease
healthcare
chronic kidney disease
palliative care
prognostic factors
diffuse large b cell lymphoma
machine learning
big data
pain management
chronic pain
deep learning
drug induced